(Q45099923)

9 December 2017

title

Fibrinogen receptor antagonists induce conformational changes of the human platelet glycoprotein IIb. (English)

1 reference

9 December 2017

author name string

Hans-Juergen Seyfarth

series ordinal

1

1 reference

9 December 2017

Mario Koksch

series ordinal

2

1 reference

9 December 2017

publication date

1 November 2004

1 reference

Cytometry Part B: Clinical Cytometry

9 December 2017

published in

1 reference

9 December 2017

volume

62

1 reference

9 December 2017

issue

1

1 reference

9 December 2017

page(s)

14-24

1 reference

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding?

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Intrinsic activating properties of GP IIb/IIIa blockers

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Evaluation of platelet membrane glycoproteins in coronary artery disease : consequences for diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

A cell-based model of hemostasis

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Markers of platelet activation in coronary heart disease patients

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Platelet function in acute myocardial infarction treated with direct angioplasty

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Flow cytometric assessment of platelet function in patients with peripheral arterial occlusive disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Cardiopulmonary bypass leads to a preferential loss of activated platelets. A flow cytometric assay of platelet surface antigens

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Large Platelets Circulate in an Activated State in Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Platelet activation markers and the primary antiphospholipid syndrome (PAPS)

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Comparative analysis of different flow cytometry-based immunophenotypic methods for the analysis of CD59 and CD55 expression on major peripheral blood cell subsets

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

HLA-DQA1*0301-Associated Susceptibility for Autoimmune Polyglandular Syndrome Type II and III

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61).

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Application of fluorescence resonance energy transfer in the clinical laboratory: routine and research

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Plasma-membrane-bound macromolecules are dynamically aggregated to form non-random codistribution patterns of selected functional elements. Do pattern recognition processes govern antigen presentation and intercellular interactions?

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Fluorescence resonance energy transfer as a new method for the epitope-specific characterization of anti-platelet antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Flow cytometric measurements of fluorescence energy transfer using single laser excitation

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.20026

7 January 2021

Identifiers

DOI

10.1002/CYTO.B.20026

1 reference

9 December 2017

1 reference